SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.18+2.4%12:52 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (15320)2/19/1998 11:34:00 AM
From: Flagrante Delictu  Read Replies (1) of 32384
 
Henry, >> ...suggest that LAZ3/BCL6 & nuclear hormone receptors repress transcription through shared mechanisms involving SMRT recruitment & histone deacetylation.<< Since LGND is THE transcription company, the ability to repress transcription is highly important to it & that ability leads to more information on how to enhance transcription by interfering with the very factors that repress it. Interestingly, LGND ceased its trials against non-Hodgkins lymphomas in '97, the same year this paper was presented. Hopefully this updated knowledge will permit a more dynamic attack against it. Bernie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext